Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Plerixafor + Temozolomide |
| Synonyms | |
| Therapy Description |
Mozobil (plerixafor) inhibits CXCR4 and CXCL12-mediated cell signaling to influence tumor metastasis (PMID: 19641136, PMID: 16815309). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Plerixafor | Mozobil | AMD3100 | CXCR4 Inhibitor 15 | Mozobil (plerixafor) inhibits CXCR4 and CXCL12-mediated cell signaling to influence tumor metastasis (PMID: 19641136, PMID: 16815309). |
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03746080 | Phase II | Plerixafor + Temozolomide | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | Completed | USA | 0 |